急性白血病患者血清白细胞介素-11及可溶性糖蛋白130水平的测定

摘要

目的 探讨白细胞介素-11(IL-11)及可溶性糖蛋白130(sgpl30)在初诊急性白血病(AL)诱导缓解过程中的变化及临床意义.方法 采用ELISA法分别对47例初诊AL患者治疗前及获完全缓解(CR)后的血清IL-11及sgp130含量进行动态观测,同时观察患者外周血白细胞和血小板数量的变化.结果 AL患者的血清IL-11水平明显低于健康对照组(P＜0.05),经过诱导化疗获CR后又明显升高并接近正常水平,且与外周血血小板数呈正相关;而sgp130水平在初诊AL患者明显高于健康对照组(P＜0.05),获CR后又明显下降,且与外周血白细胞数呈正相关.结论 检测AL患者血清IL-11及sgp130水平可作为了解AL患者病情、判断疗效和预后的有意义的指标.%Objective To explore the levels and the significance of IL-11 and soluble glycoprotein 130(sgp130) in the treatment of new-diagnosed acute leukemia(AL) during the induced remission. Methods The levels of IL-11 and sgpl30 in 47 patients with acute leukemia were determined by ELISA respectively before treatment and after completed remission(CR), and the number of white blood cell (WBC) and platelet (Plt) were valued by hametometry. Results Plasma IL-11 level of AL patients was significantly lower than normal (P ＜0.05), and increased obviously to the normal level when complete remission was achieved. And it correlated with PLT counts. While sgp130 level was higher than normal (P＜0.05),and declined after CR and correlated with WBC counts. Conclusion The plasma IL-11 and sgp130 levels can be helpful for confirming the diagnosis,evaluating the efficiency and predicting the prognosis of AL.